William Edward Pelling

Bellco SRL provides therapies and systems for the treatment of renal failure, multiple organ failure, sepsis and congestive heart failure. It offers haemodiafiltration therapies, dialysis machines equipment, haemodialysers, blood lines, catheters, concentrates, and sorbent cartridges; pathologies for acute patients; and altered haemodynamics, renal hypoperfusion, and low cardiac output therapeutic system for neonatal patients. The company was founded in 1972 and is headquartered in Mirandola, Italy.^

Ikonisys, Inc. designs and manufactures medical diagnostic products for the diagnosis of cancers. Its products include Ikoniscope Robotic Microscope that provides automated slide handling, slide scanning, real-time image capture and analysis, eliminates various factors that cause human error in testing, oncoFISH bladder that allows scanning and analysis of cells recovered from a voided urine sample. The company was founded by Pramod K. Srivastava, Petros Tsipouras, Gamil G. de Chadarevian, Michael W. Kilpatrick and Triantafyllos Tafas in 1999 and is headquartered in New Haven, CT.

Part of Fortrea Holdings, Inc., Fortrea Clinical Research Unit, Inc. is a company that engages in clinical research for pharmaceutical and biotechnology organizations. The company is based in Austin, TX.

Bracco Diagnostics, Inc. manufactures chemicals and allied products. It develops and markets diagnostic pharmaceutical products including Isovue X-ray contrast agent, ProHance MRI contrast agent and nuclear medicine products pharmaceuticals in North America. It is a subsidiary of Bracco SPA. The company is headquartered in Princeton, NJ

Bracco Imaging SpA manufactures and develops diagnostic imaging solutions for public and private hospitals, imaging centers and private practices. The firm's services include radiology, X-ray imaging, magnetic resonance imaging and ultrasound applications. The company was founded in 1985 and is headquartered in Milan, Italy.

Alzeca Biosciences, Inc. is a company based in Houston, TX. Alzeca is developing a proprietary intravenous contrast agent that targets Alzheimer's disease pathology. The company's targeted agent has shown the ability to detect early stage disease pathology with exceptional resolution and sensitivity using commonly available imaging techniques. The development of the agent was initiated through a collaboration between Dr. Ananth Annapragada and Dr. Jason Eriksen. The company was founded in 2012 by Jason Eriksen, Robin Mansukhani, Ananth Annapragada. The CEO is Carlo Giovanni Medici.